日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Accuracy of cross-sectional imaging in predicting tumor viability using the LI-RADS treatment response algorithm after image-guided percutaneous ablation with radiologic-pathologic explant correlation

利用LI-RADS治疗反应算法预测影像引导经皮消融术后肿瘤活性的横断面成像准确性及放射病理学切除标本相关性分析

期刊:Cancer Imaging
影响因子:3.5
doi:10.1186/s40644-025-00884-y
Shenoy-Bhangle, Anuradha S; Malik, M Saad; Ali, Aamir; Jiang, Nan Nancy; Andrabi, Syed Yasir; Singal, Amit; Curry, Michael P; Catana, Maria-Andreea; Eckhoff, Devin E; Faintuch, Salomao; Ahmed, Muneeb; Nasser, Imad Ahmad; Sarwar, Ammar
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD

Velacur ACE 在诊断 MASLD 方面优于 FibroScan CAP。

期刊:Hepatology Communications
影响因子:4.6
doi:10.1097/HC9.0000000000000402
Loomba, Rohit; Ramji, Alnoor; Hassanein, Tarek; Yoshida, Eric M; Pang, Emily; Schneider, Caitlin; Curry, Michael P; Afdhal, Nezam H
发表日期：2024
文献求助 收藏

The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study

使用无创 Velacur® 区分健康志愿者和慢性肝病患者：一项可行性研究

期刊:International Journal of Hepatology
影响因子:1.4
doi:10.1155/2024/8877130
Curry, Michael P; Tam, Edward; Schneider, Caitlin; Abdelgelil, Noha; Hassanien, Tarek; Afdhal, Nezam H
发表日期：2024
文献求助 收藏

Methods and Validation of Velacur Determined Fat Fraction in patients with MASLD

Velacur测定MASLD患者脂肪分数的方法及验证

期刊:
影响因子:
doi:10.1016/j.wfumbo.2024.100061
Honarvar, Mohammad; Lobo, Julio; Schneider, Caitlin; Klein, Samuel; Smith, Gordon I; Loomba, Rohit; Ramji, Alnoor; Hassanein, Tarek; Yoshida, Eric M; Pang, Emily; Curry, Michael P; Afdhal, Nezam H
发表日期：2024
文献求助 收藏

Advancing diagnosis and management of liver disease in adults through exome sequencing

利用外显子组测序推进成人肝病的诊断和治疗

期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2023.104747
Zheng, Melanie; Hakim, Aaron; Konkwo, Chigoziri; Deaton, Aimee M; Ward, Lucas D; Silveira, Marina G; Assis, David N; Liapakis, AnnMarie; Jaffe, Ariel; Jiang, Z Gordon; Curry, Michael P; Lai, Michelle; Cho, Michael H; Dykas, Daniel; Bale, Allen; Mistry, Pramod K; Vilarinho, Silvia
发表日期：2023
文献求助 收藏

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies

北美研究表明，对肝肾综合征患者早期使用特利加压素治疗可改善临床疗效。

期刊:Hepatology Communications
影响因子:4.6
doi:10.1097/01.HC9.0000897228.91307.0c
Curry, Michael P; Vargas, Hugo E; Befeler, Alex S; Pyrsopoulos, Nikolaos T; Patwardhan, Vilas R; Jamil, Khurram
发表日期：2023
文献求助 收藏

MELD, MELD 3.0, versus Child score to predict mortality after acute variceal hemorrhage: A multicenter US cohort

MELD评分、MELD 3.0评分与Child评分在预测急性食管静脉曲张出血后死亡率方面的比较：一项美国多中心队列研究

期刊:Hepatology Communications
影响因子:4.6
doi:10.1097/HC9.0000000000000258
Buckholz, Adam; Wong, Rochelle; Curry, Michael P; Baffy, Gyorgy; Chak, Eric; Rustagi, Tarun; Mohanty, Arpan; Fortune, Brett E
发表日期：2023
文献求助 收藏

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome

特利加压素对肝肾综合征患者肾脏替代治疗的影响

期刊:Kidney360
影响因子:3
doi:10.34067/KID.0000000000000132
Velez, Juan Carlos Q; Wong, Florence; Reddy, K Rajender; Sanyal, Arun J; Vargas, Hugo E; Curry, Michael P; Gonzalez, Stevan A; Pappas, S Chris; Jamil, Khurram
发表日期：2023
文献求助 收藏

Post-Transplant Hepatic Steatosis: A Condition Not to Overlook

移植后肝脂肪变性：不容忽视的疾病

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm12237340
Alabdul Razzak, Iyiad; Curry, Michael P; Lai, Michelle; Trivedi, Hirsh D
发表日期：2023
文献求助 收藏

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure

特利加压素在1型肝肾综合征和重度急性加重型慢性肝衰竭患者中的应用及呼吸衰竭

期刊:Alimentary Pharmacology & Therapeutics
影响因子:6.7
doi:10.1111/apt.17195
Wong, Florence; Pappas, Stephen Chris; Reddy, K Rajender; Vargas, Hugo; Curry, Michael P; Sanyal, Arun; Jamil, Khurram
肝衰竭
毒理研究
发表日期：2022
文献求助 收藏